No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TMDX240517C77500
- 14.50
- 0.000.00%
15min DelayTrading Apr 17 14:03 ET
0.00High0.00Low
0.00Open14.50Pre Close0 Volume1 Open Interest77.50Strike Price0.00Turnover0.00%IV-0.43%PremiumMay 17, 2024Expiry Date52.76Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma2.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Insider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX)
TransMedics(TMDX.US) Officer Sells US$1.92 Million in Common Stock
$TransMedics(TMDX.US)$ Officer Gordon Stephen sold 15,000 shares of common stock on May 6, 2024 at an average price of $128 for a total value of $1.92 million.Source: Announcement What is statement of
TransMedics(TMDX.US) Director Sells US$930.28K in Common Stock
$TransMedics(TMDX.US)$ Director Basile Edward M sold 7,157 shares of common stock on May 7, 2024 at an average price of $129.98 for a total value of $930.28K.Source: Announcement What is statement of
TransMedics(TMDX.US) Officer Sells US$759.48K in Common Stock
$TransMedics(TMDX.US)$ Officer Khayal Tamer I sold 5,839 shares of common stock on May 6, 2024 at an average price of $130.07 for a total value of $759.48K.Source: Announcement What is statement of ch
TransMedics(TMDX.US) Officer Sells US$418.57K in Common Stock
$TransMedics(TMDX.US)$ Officer Corcoran Nicholas sold 3,222 shares of common stock on May 6, 2024 at an average price of $129.91 for a total value of $418.57K.Source: Announcement What is statement of
TransMedics(TMDX.US) Officer Sells US$3.9 Million in Common Stock
$TransMedics(TMDX.US)$ Officer Hassanein Waleed H sold 30,000 shares of common stock on May 6, 2024 at an average price of $130.07 for a total value of $3.9 million.Source: Announcement What is statem
Comments
TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
1
$Advanced Micro Devices(AMD.US$ was obvious to buy at $100 and many waited
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
9
3
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Insider selling over the past year, particularly in recent months, may indicate insiders believe shares are overpriced. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership shows alignment with shareholders, but past sales warrant caution.
Read more